We bought $IDRA with a price target opinion of $6-$6.25. Idera expects to report top-line data from the first three dosing groups of the Phase II trial for Psoriasis in the first quarter of 2014 and to report top-line data…
Author: Scott Matusow
Video: Charts and Commentary For Feb 20, 2014
Charts and Commentary For Feb 20, 2014. $SGYP $NEON $HALO $ACRX $MNKD $SYN $PRAN reviewed + Market commentary and outlook. There is a slight humming sound in video for some reason that happens every now and then, but nothing bad.…
Scott, Kyle, and Mike bought $SGYP
We like the chart and feel it’s about to pop. We will definitely cover it again over the next few weeks. Our 1 year Price target opinion remains at $11 to $12, we think their data will all confirm as…
Video: Market Commentary $PRAN and $CHTP + Charts Feb 15, 2014
Market Commentary on $PRAN and $CHTP + Charts Feb 15, 2014. Brief chart reviews for $SGYP, $SYN, $ACRX and $NEON Prana reported endpoints met on its P2 study regarding Hunnington’s disease (HD). Feuerstein calls it a fail which is very disingenuous.…
Additional Commentary and Conclusion: Synthetic Biologics P2 Combo Trial’s Significance Explained
Video: Synthetic Biologics P2 Combo Drug Trial Explained. In this video, I explain why this trial is more significant than some might think. I explain $TEVA’S Copaxone patent expiry situation along with $SYN’s patent on this form of Trimesta and…
$CHTP Short Trade Thesis
Currently I’m 3k short on $CHTP at around current price. if CRL, then it drops down to the 1.50 range, i make money. If approval, it over gaps, where I will short at least 7k more, average up, make money.…
Significant Upcoming Catalysts For These Biotechs Should Provide Alpha Opportunity
This week we want to highlight several biotechs with catalysts coming up in the near future. These price driving catalysts may include FDA approval decisions, FDA Advisory Committee (ADCOM) recommendations, product launches, and clinical data releases. These catalysts usually gain…
UPDATED: We bought $SYN, Think it will be a big runner
Catalyst Trade Alert: We bought $SYN, Think it will be a big runner. Randal Kirk play, same guy who is heavy with $HALO. We feel $SYN could run up over $5 a share in the next 2 months or so.…
Trade Alert: We Bought $ROSG Target Opinion – $4.35 – $4.50
Trade Alert: We Bought $ROSG Target Opinion – $4.35 – $4.50, possible break out to challenge 52 week high of $5.25. Chart indicates MACD cross coming, good short interest, nice wedge, Will hit resistance around $4.35 I have marked the…
Chart Reviews For Feb.13, 2014
Chart Reviews For Feb.13, 2014. As promised, $NEON and $BGMD reviewed + $HALO $ACRX and $SGYP. Teaser preview of upcoming catalyst trade pick from us and a bit more, enjoy! Scott
